On 22 September 2020, the King Abdullah International Medical Research Center (KAIMRC), a leading biomedical and clinical R&D and Innovation Center, and IQVIA, a leading global provider of services and solutions to the life sciences industry, signed a memorandum of understanding to collaborate on a unique database for COVID-19.
The database, powered by the E360™ SaaS platform, will enable researchers and clinicians to generate real world evidence for a better-informed COVID-19 pandemic response and design and execute a series of observational studies. E360 will also help researchers answer relevant clinical study questions including prognosis and natural history, treatment effectiveness and safety, and help provide a more reliable prediction of patient outcomes.
“This data set will be of great benefit to the clinical research community through the newly set up Saudi Clinical Trials Network,” said Dr. Ahmed Alaskar, Executive Director, KAIMRC.
“We are thrilled to work with KAIMRC on this scientific initiative,” Mohamed Mostafa, general manager of IQVIA Saudi Arabia and Egypt, said. “This collaboration will provide all clinical and evidence generation activities on COVID-19 research through IQVIA’s unique platform, E360.”
